Pharmacothérapie des troubles du comportement dans l’autisme avec déficit intellectuel (notice n° 679659)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 04441cam a2200397 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250121202642.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Pommepuy, Noël |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Pharmacothérapie des troubles du comportement dans l’autisme avec déficit intellectuel |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2018.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 15 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | RésuméDe nombreuses publications existent dans le champ « autisme et psychotropes », mais on constate une grande disparité dans les objectifs, les méthodes, les résultats et les risques d’effets indésirables, qui conduit à une absence de consensus. Cependant la fréquence importante des troubles du comportement chez les sujets autistes avec déficit intellectuel, probablement les plus complexes à aborder sur le plan thérapeutique et les plus vulnérables eu égard aux effets indésirables, met le clinicien devant une difficulté à évaluer le moment du recours au traitement médicamenteux, l’efficience pratique et l’innocuité de ce dernier. Dans cet article, nous décrivons une méthode d’analyse complexe des problèmes comportementaux chez ces sujets (dont la plupart interviennent dans une interaction avec le contexte) avant de proposer une modalité décisionnelle de choix, de conduite et d’évaluation de la prescription basée sur les données de la littérature, le repérage d’une cible thérapeutique et la prise en compte du profil d’innocuité de la molécule. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Pharmacotherapy of behavioral disorders in autism with intellectual deficit. Clinical approach for the prescriberMany publications exist in the field of “autism and psychotropics”, but there remains a great disparity in the objectives, methods, results and risks of adverse effects, which leads to a lack of consensus. However, the high incidence of behavioral disorders in intellectually impaired autistic subjects, who are probably the most complex to approach therapeutically and who are most vulnerable to adverse effects, makes it difficult for clinicians to assess the timing of treatment, medication, the practical efficacy and the safety of the latter. In this article, we describe a method of complex analysis of behavioral problems in these patients (most of whom intervene in an interaction with the context) before proposing a decisional modality of choice, conduct and evaluation of the prescription based on data from the literature, the identification of a therapeutic target and the consideration of the safety profile of the molecule. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | ResumenExisten numerosas publicaciones en el campo “autismo y psicótropos”, pero se constata una gran disparidad en los objetivos, métodos, resultados y riesgos de efectos indeseados, la cual lleva a una ausencia de consenso. Sin embargo la importante frecuencia de los trastornos del comportamiento en los sujetos autistas con déficit intelectual, probablemente los más complejos para abordarlos a nivel terapéutico y más vulnerables debido a sus efectos indeseados, pone al médico clínico ante una dificultad para evaluar el momento de recurrir al tratamiento medicamentoso, o sea la eficiencia práctica y la inocuidad del mismo. En este artículo, describimos un método de análisis complejo de los problemas comportamentales en estos sujetos (una mayoría de los que intervienen en una interacción con el contexto) antes de proponer una modalidad de decisión, de conducción y de evaluación de la prescripción fundada en los datos de la literatura, la detección de una meta terapéutica y la toma en cuenta de un perfil de inocuidad de la molécula. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | retard mental |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | adaptation sociale |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | autisme |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | trouble envahissant du développement |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | antidépresseur |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | trouble du comportement |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | thérapeutique médicamenteuse |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | psychotrope |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | neuroleptique |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | social adjustment |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | autism |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | drug therapy |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | mental retardation |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | pervasive developmental disorder |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | psychotropic |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | antidepressant |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | neuroleptic |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | behavioral disorder |
| 786 0# - DATA SOURCE ENTRY | |
| Note | L'information psychiatrique | Volume 94 | 6 | 2018-07-24 | p. 485-499 | 0020-0204 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-l-information-psychiatrique-2018-6-page-485?lang=fr&redirect-ssocas=7080">https://shs.cairn.info/revue-l-information-psychiatrique-2018-6-page-485?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux